The Effect of Respiratory Rehabilitation on Systemic Inflammation in COPD - Myokine Action and Muscle-Bone Crosstalk - - The Effect of Respiratory Rehabilitation on Systemic Inflammation in COPD - Myokine Action and Muscle-Bone Crosstalk

Gunma University0 sites30 target enrollmentApril 30, 2023

ConditionsChronic obstructive pulmonary disease

Overview

Phase: 未知
Intervention: Not specified
Conditions: Chronic obstructive pulmonary disease
Sponsor: Gunma University
Enrollment: 30
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 30, 2023

End Date

March 31, 2028

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Gunma University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. Patients who need assistance from others when moving indoors, and who need a walking aid other than a cane or drip stand when walking. 2\. Patients who have had a short\-term exacerbation within the past 4 weeks of the study entry, according to the GOLD definition. 3\. Patients with blood sputum of unknown cause. 4\. Patients with angina pectoris, unstable cardiovascular disease, or aortic aneurysm. 5\. Patients diagnosed with myocardial infarction or pulmonary embolism 6\. Have undergone eye surgery (cataract or glaucoma) within the past 4 weeks from the date of study entry. 7\. Underwent thoracic or abdominal surgery within the past 4 weeks from the date of study entry. 8\. Those who are unable to give explanation and consent due to cognitive functional aspects or psychiatric symptoms. 9\. Those who need anti\-inflammatory drugs (oral steroids, NSAIDs, etc.) as treatment. 10\. Patients who cannot discontinue active vitamin D3 preparations for the treatment of osteoporosis. 11\. Regular use of vitamins, protein drinks, amino acids, or other beverages or supplements in the past month. 12\. Patients with chronic kidney disease whose urinalysis shows proteinuria of 0\.15 g/gcr or more, or whose eGFR is less than 60 mL/min/1\.73 m2, or both have persisted for more than 3 months. Patients with chronic kidney disease or other renal diseases. 13\. Patients with a diagnosis of liver dysfunction such as acute hepatitis, chronic hepatitis, fatty liver, cirrhosis, etc. 14\. Patients who have regularly exercised for at least 60 minutes every week for at least 3 METs of breathless and sweaty exercise, such as running or water exercise, during the past 3 months.